Achilles Therapeuticsの空売り状況は、投資家がAchilles Therapeuticsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Achilles Therapeutics (NASDAQ:ACHL) 株価情報, 空売り情報

Achilles Therapeutics

Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.

Achilles Therapeutics plc - American Depositary Shares

Achilles Therapeutics PLC

WIIM

DXCM

Dexcom Sees FY25 Adj. EBITDA Margin 30%, Revenue Growth 14%, Revenue $4.60B.

Air Lease (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AL#NYSE">AL</a>) reported quarterly earnings of $1.34 per share which beat the analyst consensus estimate of $0.74 by 81.08 percent. This is a 30.21 percent decrease over earnings of $1.92 per share from the same period last year. The company reported quarterly sales of $712.89 million which beat the analyst consensus estimate of $704.03 million by 1.26 percent. This is a 0.51 percent decrease over sales of $716.57 million the same period last year.

Earnings

Earnings Beats

News

Air Lease Q4 2024 Adj EPS $1.34 Beats $0.74 Estimate, Sales $712.89M Beat $704.03M Estimate

President Donald Trump announced Thursday a roadmap for enacting reciprocal tariffs on countries that impose <a href="https://www.benzinga.com/news/econ-s">duties on U.S. goods.</a>
Despite the announcement, investors remained unshaken, as the move had been widely expected following Trump&#8217;s hints the previous week. Additionally, with the plan still in a study phase until April 1, it creates a window for potential negotiations with trading partners.
The S&amp;P 500 – tracked by the SPDR S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) – rallied by 1% by 3:20 p.m. ET, trading at a less than 0.1 percentage points below record highs. 
The Nasdaq 100 – as broadly followed by the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) – soared 1.3%. The dollar tumbled 0.8%, recording its worst day since Jan. 20, while gold traded at $2,930 per ounce, heading towards the highest daily close ever. 
<h3 class="wp-block-heading">Matching Foreign Tariffs: &#8216;A Beautiful, Simple System&#8217;</h3>
Trump's proposal would mirror tariffs imposed by other nations on U.S. exports.
&#8220;Whatever they charge us, we&#8217;re charging them. So it works out very well. It&#8217;s a beautiful, simple system,&#8221; Trump said. 
&#8220;Reciprocal makes tariffs really fair. There won&#8217;t be any exemptions.&#8221;
Trump specifically mentioned India as an example of a country where high tariffs make it difficult for U.S. companies to compete.
&#8220;I remember when Harley-Davidson couldn&#8217;t sell their motorbikes into India because the tariff was so high,&#8221; Trump said.
Trump indicated that companies could avoid tariffs altogether by manufacturing in the U.S.
&#8220;They can build a factory here, a plant or whatever it might be. That includes medical, cars, chips, semiconductors—everything. If you build here, you have no tariffs whatsoever. And I think that&#8217;s what&#8217;s going to happen. Our country is going to be flooded with jobs.&#8221;
<h3 class="wp-block-heading">Impact On Prices, Government Revenue</h3>
When asked whether prices could rise due to new tariffs, Trump indicated that short-term price increases could occur but argued that long-term effects would be positive for American workers.
&#8220;Prices could go up somewhat short term, but prices will also go down. It's going to mean tremendous amounts of jobs,&#8221; he said.
When asked how much revenue the tariffs could generate annually, Trump predicted a &#8220;staggering&#8221; financial boost for the U.S. government.
&#8220;This is going to be the thing that makes our country really prosperous again. And this is going to be what pays down the $36 trillion in debt,&#8221; Trump said.
<h3 class="wp-block-heading">Tough Trade Talks Ahead With EU, Canada</h3>
Trump also singled out the European Union, criticizing its 20% value-added taxes an unfair trade barrier.
&#8220;The EU has been very nasty. They haven't treated us properly,&#8221; he said, adding that Brussels imposes additional fees that he said disadvantage U.S. businesses.
Trump said that if Canada were to become the 51st state, Canadians would benefit from lower taxes and improved security.
&#8220;I think Canada is going to be a very serious contender to be our 51st state,&#8221; Trump said.
<h3 class="wp-block-heading">Global Trade And Geopolitical Moves</h3>
Beyond trade, Trump stated Thursday that Ukraine should have a seat at the table in any peace negotiations with Russia.
&#8220;I do believe Putin really wants peace,&#8221; he said.
Regarding Russia&#8217;s possible return to the G8, Trump reiterated his stance that excluding Moscow was a mistake.
&#8220;They should be sitting at the [G8] table. I think Putin would love to be back,&#8221; he said.
Trump also warned BRICS nations against attempting to undermine the U.S. dollar.
&#8220;If they want to play games with the dollar, then they&#8217;re going to be hit with a 100% tariff,&#8221; he said.
Read Next: 
<ul>
<li><a href="http://benzinga.com/economics/macro-economic-events/25/02/43708650/stocks-rise-despite-hot-producer-inflation-intel-soars-bitcoin-drops-below-96000-whats-driving-markets-thursday">Stocks Rise Despite Hot Producer Inflation, Intel Soars, Bitcoin Drops Below $96,000: What&#8217;s Driving Markets Thursday?</a></li>
</ul>

Government

Macro Economic Events

Regulations

Broad U.S. Equity ETFs

Politics

Global

Economics

ETFs

Trump Launches Plan For 'Reciprocal Tariffs:' S&P 500 Nears Record Highs, Dollar Tumbles

Business Outlook
Applied's total net revenue, non-GAAP gross margin and non-GAAP diluted EPS for the second quarter of fiscal 2025, including the estimated impact of recently announced U.S. export regulations, are expected to be approximately as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="7">Q2 FY2025</td>
</tr>
<tr>
<td>(In millions, except percentage and per share amounts)</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Total net revenue</td>
<td>$</td>
<td>7,100</td>
<td>+/-</td>
<td>$</td>
<td>400</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Non-GAAP gross margin</td>
<td>48.4</td>
<td>%</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Non-GAAP diluted EPS</td>
<td>$</td>
<td>2.30</td>
<td>+/-</td>
<td>$</td>
<td>0.18</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
This outlook for non-GAAP diluted EPS excludes known charges related to completed acquisitions of $0.01 per share and a gain on asset sale of $0.05 per share, and includes a net income tax benefit related to intra-entity intangible asset transfers of $0.04 per share, but does not reflect any items that are unknown at this time, such as any additional charges related to acquisitions or other non-operational or unusual items, as well as other tax-related items, which we are not able to predict without unreasonable efforts due to their inherent uncertainty.

Guidance

AMAT

Applied Materials Sees Q2 EPS $2.30+/- $0.18 Vs $2.30 Est.; Revenue $7.1B+/- $400M Vs $7.21B Est.

Innovative Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISSC#NASDAQ">ISSC</a>) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.12 by 66.67 percent. This is a 33.33 percent decrease over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $15.97 million which beat the analyst consensus estimate of $12.23 million by 30.52 percent. This is a 71.56 percent increase over sales of $9.31 million the same period last year.

Earnings Misses

ISSC

Innovative Solns Q1 EPS $0.04 Misses $0.12 Estimate, Sales $15.97M Beat $12.23M Estimate

WYNN

Wynn Resorts shares are trading higher following a Q4 earnings beat.

Vanda Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) sees FY2025 sales of $210.000 million-$250.000 million vs $284.90 million analyst estimate.

VNDA

Vanda Pharma Sees FY2025 Sales $210.000M-$250.000M vs $284.90M Est

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) reported quarterly earnings of $0.45 per share which missed the analyst consensus estimate of $0.50 by 10 percent. This is a 10 percent decrease over earnings of $0.50 per share from the same period last year. The company reported quarterly sales of $1.140 billion which beat the analyst consensus estimate of $1.104 billion by 3.22 percent. This is a 10.20 percent increase over sales of $1.034 billion the same period last year.

DexCom Q4 2024 Adj. EPS $0.45 Misses $0.50 Estimate, Sales $1.140B Beat $1.104B Estimate

Wynn Resorts Q4 2024 Adj. EPS $2.42 Beats $1.22 Estimate, Sales $1.840B Beat $1.769B Estimate

RARE

Ultragenyx Pharmaceutical Sees FY25 Revenue $640M-$670M Vs $652.946M Est.

Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) reported quarterly earnings of $2.38 per share which beat the analyst consensus estimate of $2.29 by 3.93 percent. This is a 11.74 percent increase over earnings of $2.13 per share from the same period last year. The company reported quarterly sales of $7.17 billion which beat the analyst consensus estimate of $7.14 billion by 0.35 percent. This is a 6.84 percent increase over sales of $6.71 billion the same period last year.

Applied Mat Q1 Adj $2.38 Beats $2.29 Estimate, Sales $7.17B Beat $7.14B Estimate

Vanda Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.11) by 27.27 percent. This is a 100 percent decrease over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $53.19 million which beat the analyst consensus estimate of $52.25 million by 1.79 percent. This is a 17.48 percent increase over sales of $45.27 million the same period last year.

Vanda Pharma Q4 EPS $(0.08) Beats $(0.11) Estimate, Sales $53.19M Beat $52.25M Estimate

Virpax Pharmaceuticals, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced the completion of the full study that followed the initial Probudur&#x2122; pilot study performed by the U.S. Army Institute of Surgical Research (USAISR) under an existing Cooperative Research and Development Agreement (CRADA).
The USAISR is the U.S. Department of Defense's premier research organization for developing solutions for trauma and critical care challenges in combat casualties. This study was designed to determine if Probudur reduces pain behaviors in a rat model of incisional pain. The surgical procedures and assessments were identical to those in the pilot study. The study compared Probudur with free bupivacaine and EXPAREL&#xAE;.
Various concentrations of Probudur were injected into the tissue around the incision site as well as a saline solution for the control group. The doses of Probudur showed reduction in incision-induced pain behaviors. "These positive results are consistent with what we at Virpax have previously observed and we are encouraged by these findings," commented Jatinder Dhaliwal, Chief Executive Officer of Virpax.
Probudur is being developed to achieve the overall goal of safe and effective pain control during the perioperative period and to significantly reduce or eliminate the need for opioids after surgery in approved indications. Probudur is a local anesthetic that binds to the sodium channels, preventing pain signals from reaching the brain. In preclinical studies, Probudur has shown long duration pain control for at least 96 hours, with a rat incisional model demonstrating analgesia for up to five days and in vitro studies demonstrating a slow release of bupivacaine that lasted for up to six (6) days.

Biotech

General

VRPX

Virpax Confirms Results With U.S. Army With Probudur For Combat Care Study, Showing Incision Pain Reduction In Rat Model, Aiming To Reduce Opioid Need; Long Duration Pain Control Demonstrated Up To 5 Days

Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(1.29) by 7.75 percent. This is a 8.55 percent increase over losses of $(1.52) per share from the same period last year. The company reported quarterly sales of $164.877 which missed the analyst consensus estimate of $155.393 million by 100.00 percent. This is a 100.00 percent decrease over sales of $127.392 million the same period last year.

Ultragenyx Pharmaceutical Q4 2024 GAAP EPS $(1.39) Misses $(1.29) Estimate, Sales $164.877 Miss $155.393M Estimate

As a company that has effectively transitioned into a proxy wager for the cryptocurrency market, MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) must take the good with the bad. On the positive side of the spectrum, the returns of MSTR stock during its <a href="https://www.benzinga.com/topic/microstrategy">decisively bullish cycles</a> are nothing short of extraordinary. However, on the negative side, MSTR tends to be incredibly volatile — hardly surprising given that it acts like a crypto alternative.
Largely coinciding with the digital asset ecosystem, MicroStrategy saw its equity value peak late last year. Since then, broader economic, social and geopolitical concerns have weighed on investor sentiment. At the moment, <a href="https://www.benzinga.com/news/global/25/02/43618203/gold-nears-3000-but-miners-struggle-as-rising-costs-squeeze-profits">gold bullion</a> — the traditional safe-haven asset — has been the category to watch. Still, with <a href="https://www.benzinga.com/trading-ideas/movers/25/02/43681236/bitcoin-ethereum-dogecoin-spike-amid-hotter-than-expected-inflation-numbers-eths-decisive-move-above-3000-could-restore-confidence-says-analyst">inflation coming in hotter than expected</a>, several leading cryptos enjoyed a sizable pop recently.
While precious metals tend to attract buying demand during inflationary periods, it's not at all shocking to see blockchain assets absorb some of the safe-haven market share. As data from Bank of America Private Bank revealed last year, millennial investors who have at least $3 million are <a href="https://www.benzinga.com/startups/24/10/41232614/young-millionaires-are-betting-17-of-their-portfolios-on-crypto-and-theyre-the-conservative-ones">piling aggressively into cryptos</a>.
As the asset of choice among young people, MicroStrategy stands on solid ground. Interestingly, amid the optimistic fundamental backdrop, MSTR stock appears to be charting a buy signal. Specifically, a triangular shape has formed, reminiscent of a <a href="https://www.benzinga.com/money/stock-chart-patterns">bullish pennant formation</a>.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="582" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13054717/MSTR-stock-bullish-pennant-1024x582.jpg" alt="" class="wp-image-780691" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13054717/MSTR-stock-bullish-pennant-1024x582.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13054717/MSTR-stock-bullish-pennant-300x170.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13054717/MSTR-stock-bullish-pennant-768x436.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13054717/MSTR-stock-bullish-pennant.jpg 1051w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by TradingView</figcaption></figure>
Granted, standard technical analysis is interpretive, which naturally generates skepticism. However, the empirical framework also supports the bullish angle, making MSTR stock a tempting (albeit high-risk) proposition.
<h2 class="wp-block-heading">Playing MSTR Stock by the Numbers</h2>
One of the benefits of investing in a relatively saccharine investment like the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) is that investors can bank on the <a href="https://www.benzinga.com/trading-ideas/24/06/39164841/june-historically-a-weak-month-for-stocks-with-negative-average-returns-over-last-20-years">upward bias</a> of the benchmark equities index. What may catch some folks off guard is that MSTR stock likewise leans northward, at least when considering the parameters of the trailing five years.
From a stochastic or temporal view of the data, a position in MSTR entered at the beginning of the week has about a 53.2% chance of rising by the end of it. Over the course of a four-week period, the long odds actually inch forward at 53.82%. Place enough bets and theoretically, speculators should noticeably win more than they lose.
Circumstances get even more intriguing when considering dynamic probabilities — probabilities based on certain conditions being true. The best way to think about this is the difference between a baseball player's batting average over a season (stochastic) versus that player's batting average when runners are in scoring position (dynamic).
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13055610/MSTR-stock-probability-gambit-1024x576.jpg" alt="" class="wp-image-780710" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13055610/MSTR-stock-probability-gambit-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13055610/MSTR-stock-probability-gambit-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13055610/MSTR-stock-probability-gambit-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13055610/MSTR-stock-probability-gambit.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
For example, last week, MSTR stock gained roughly 5.7%. Whenever MSTR gains between 5% and 10% in a one-week period, the subsequent week enjoys long odds of 64.71%. This metric improves to 67.7% through the end of the third week and ultimately slips to 58.82% by the end of the fourth week. Still, the evidence seems clear: modest (at least for MSTR stock) strength fuels FOMO or the fear of missing out.
Recall that FOMO is a powerful emotion. Earlier, I identified Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) as a <a href="https://www.benzinga.com/25/02/43543843/cathie-wood-sells-pltr-stock-ignores-fomo-fuel">FOMO stock</a>, despite already enjoying remarkable upside. As of this writing, PLTR continues to march higher. I also <a href="https://www.benzinga.com/news/earnings/25/02/43638984/hood-stock-unusual-options-activity-q4-earnings">said the same thing</a> about Robinhood Markets Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) before its big earnings blowout.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43708938/5-robinhood-analysts-react-to-blowout-q4-earnings-can-the-tremendous-momentum-continue">5 Robinhood Analysts React To &#8216;Blowout&#8217; Q4 Earnings: Can The &#8216;Tremendous Momentum&#8217; Continue?</a>
<h2 class="wp-block-heading">A Risky but Rare Opportunity</h2>
 From a holistic perspective, MSTR stock — while being wildly risky on account of being a crypto proxy — is simultaneously enticing. It's a rare opportunity, combining compelling fundamental, technical and statistical catalysts. While a volatility play could be prudent, the evidence seems to lean heavily toward the northbound direction.
The magnitude of bullishness, though, is the question. Under the previously calculated dynamic odds, over a four-week period, the median return under the positive scenario stands at an astounding 32%. Under the negative scenario, the median loss sits at 11.5%.
Based on the implications of the bullish pennant formation, it's not impossible to see a 30%-plus breakout move. However, arguably most investors might find that to be too much of a stretch. On the other hand, a 10% move within a few weeks should be quite reasonable.
One idea to consider, then, is the 355/360 <a href="https://www.benzinga.com/money/bull-spread">bull call spread</a> for the options chain expiring March 7. This transaction involves buying the $355 call and simultaneously selling the $360 call. Speculators are aiming for MSTR stock to reach $360 or above, triggering the maximum reward.
To be clear, a bull spread caps the risk and the reward. However, one of the benefits of this multi-leg options strategy is that the sale of the short call helps offset the debit paid for the long call, effectively discounting the net bullish position.
Plus, with a debit paid at time of writing of $210 (which is the most that can be lost in the trade) for the chance to earn $290, the positional risk is manageable. More importantly, the data implies that the probabilistic risk is more reasonable than meets the eye.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43583287/michael-saylor-declares-death-to-blue-lines-long-live-green-dots-is-strategys-btc-purchase-streak-about-to-resume">Michael Saylor Declares &#8216;Death To Blue Lines, Long Live Green Dots:&#8217; Is Strategy&#8217;s BTC Purchase Streak About To Resume?</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Long Ideas

Options

Movers

HOOD

MSTR

PLTR

Options Corner: Crypto Proxy MicroStrategy Could Be Flashing Buy Signal

HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) underwent analysis by 29 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">16</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">5</td>
<td align="right">9</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $863.14, along with a high estimate of $980.00 and a low estimate of $725.00. This current average reflects an increase of 14.0% from the previous average price target of $757.14. 
<img src="https://www.benzinga.com/files/images/story/2025/1739480475_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of HubSpot among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nick Altmann</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$900.00</td>
<td>$825.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$885.00</td>
<td>$690.00</td>
</tr>
<tr>
<td>Brian Peterson</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$980.00</td>
<td>$750.00</td>
</tr>
<tr>
<td>Gabriela Borges</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$900.00</td>
<td>$783.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$950.00</td>
<td>$825.00</td>
</tr>
<tr>
<td>Ken Wong</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$900.00</td>
<td>$850.00</td>
</tr>
<tr>
<td>Mark Murphy</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$850.00</td>
<td>$725.00</td>
</tr>
<tr>
<td>Jackson Ader</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$920.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$940.00</td>
<td>$835.00</td>
</tr>
<tr>
<td>Parker Lane</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$925.00</td>
<td>$880.00</td>
</tr>
<tr>
<td>Taylor McGinnis</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$775.00</td>
<td>$740.00</td>
</tr>
<tr>
<td>Terry Tillman</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$900.00</td>
<td>$750.00</td>
</tr>
<tr>
<td>Joshua Reilly</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$900.00</td>
<td>$730.00</td>
</tr>
<tr>
<td>Ryan Macwilliams</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$815.00</td>
<td>$725.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$898.00</td>
<td>$835.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$900.00</td>
<td>$710.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$808.00</td>
<td>$640.00</td>
</tr>
<tr>
<td>Mark Murphy</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$725.00</td>
<td>$635.00</td>
</tr>
<tr>
<td>Drew Foster</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$900.00</td>
<td>$750.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$835.00</td>
<td>$810.00</td>
</tr>
<tr>
<td>Samad Samana</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$900.00</td>
<td>$860.00</td>
</tr>
<tr>
<td>Ryan Macwilliams</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$725.00</td>
<td>$650.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$835.00</td>
<td>$747.00</td>
</tr>
<tr>
<td>Nick Altmann</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$825.00</td>
<td>$700.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$810.00</td>
<td>$750.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$825.00</td>
<td>$750.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$850.00</td>
<td>$780.00</td>
</tr>
<tr>
<td>Siti Panigrahi</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$775.00</td>
<td>$725.00</td>
</tr>
<tr>
<td>Parker Lane</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$880.00</td>
<td>$750.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to HubSpot. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of HubSpot compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of HubSpot's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of HubSpot's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HUBS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on HubSpot analyst ratings.</a>
<h2>Delving into HubSpot's Background</h2>
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
<h3>Financial Insights: HubSpot</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: HubSpot displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 20.12%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: HubSpot's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 1.22%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): HubSpot's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.49%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): HubSpot's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.24%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: HubSpot's debt-to-equity ratio is below the industry average at 0.43, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

HUBS

A Glimpse Into The Expert Outlook On HubSpot Through 29 Analysts

During the last three months, 11 analysts shared their evaluations of CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $69.55, a high estimate of $80.00, and a low estimate of $60.00. This current average has increased by 5.09% from the previous average price target of $66.18. 
<img src="https://www.benzinga.com/files/images/story/2025/1739480467_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of CVS Health among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$73.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$76.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$73.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$75.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$60.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Maintains</td>
<td>Buy</td>
<td>$66.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Charles Ryhee</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$64.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$67.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$66.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CVS Health. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CVS Health compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for CVS Health's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into CVS Health's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CVS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CVS Health analyst ratings.</a>
<h2>Get to Know CVS Health Better</h2>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.
<h3>CVS Health's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: CVS Health displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 6.31%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 0.09%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): CVS Health's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.12%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.03%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: CVS Health's debt-to-equity ratio is below the industry average. With a ratio of 1.1, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 11 Analysts Discuss CVS Health Stock

Throughout the last three months, 10 analysts have evaluated Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $129.0, a high estimate of $140.00, and a low estimate of $119.00. This upward trend is apparent, with the current average reflecting a 0.16% increase from the previous average price target of $128.80.
<img src="https://www.benzinga.com/files/images/story/2025/1739480453_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of Blueprint Medicines by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Brian Cheng</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$129.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$119.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Reni Benjamin</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$125.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$124.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Reni Benjamin</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$125.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Reni Benjamin</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$125.00</td>
<td>$125.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Blueprint Medicines. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Blueprint Medicines compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Blueprint Medicines's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Blueprint Medicines's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BPMC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Blueprint Medicines analyst ratings.</a>
<h2>Get to Know Blueprint Medicines Better</h2>
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
<h3>A Deep Dive into Blueprint Medicines's Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Blueprint Medicines's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 126.61% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -43.9%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Blueprint Medicines's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -17.77%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Blueprint Medicines's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -4.68%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Blueprint Medicines's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.51, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BPMC

Breaking Down Blueprint Medicines: 10 Analysts Share Their Views

In the latest quarter, 14 analysts provided ratings for Equinix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>), showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">11</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $1074.57, a high estimate of $1200.00, and a low estimate of $822.00. Witnessing a positive shift, the current average has risen by 4.48% from the previous average price target of $1028.46.
<img src="https://www.benzinga.com/files/images/story/2025/1739480446_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Equinix by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maher Yaghi</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$1033.00</td>
<td>$1114.00</td>
</tr>
<tr>
<td>Ari Klein</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$1065.00</td>
<td>$1085.00</td>
</tr>
<tr>
<td>Timothy Horan</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$975.00</td>
<td>$950.00</td>
</tr>
<tr>
<td>Eric Luebchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$1065.00</td>
<td>$1075.00</td>
</tr>
<tr>
<td>Greg Miller</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$1200.00</td>
<td>$1200.00</td>
</tr>
<tr>
<td>Greg Miller</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$1200.00</td>
<td>$1200.00</td>
</tr>
<tr>
<td>Eric Luebchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$1075.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>Greg Miller</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$1200.00</td>
<td>-</td>
</tr>
<tr>
<td>Maher Yaghi</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$1114.00</td>
<td>$985.00</td>
</tr>
<tr>
<td>Jonathan Atkin</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1025.00</td>
<td>$936.00</td>
</tr>
<tr>
<td>Eric Luebchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1100.00</td>
<td>$985.00</td>
</tr>
<tr>
<td>Anthony Hau</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$1090.00</td>
<td>$935.00</td>
</tr>
<tr>
<td>Erik Rasmussen</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$1080.00</td>
<td>$995.00</td>
</tr>
<tr>
<td>Tim Long</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$822.00</td>
<td>$810.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Equinix. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Equinix compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Equinix's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EQIX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Equinix analyst ratings.</a>
<h2>About Equinix</h2>
Equinix operates 260 data centers in 71 markets worldwide. It generates 44% of total revenue in the Americas, 35% in Europe, the Middle East, and Africa, and 21% in Asia-Pacific. The firm has more than 10,000 customers, including 2,100 network providers, that are dispersed over five verticals: cloud and IT services, content providers, network and mobile services, financial services, and enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from interconnection. Equinix operates as a real estate investment trust.
<h3>Unraveling the Financial Story of Equinix</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Equinix's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 6.79%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 13.49%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Equinix's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.3%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Equinix's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.87%, the company showcases efficient use of assets and strong financial health.
Debt Management: Equinix's debt-to-equity ratio is below the industry average at 1.41, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EQIX

Equinix Stock: A Deep Dive Into Analyst Perspectives (14 Ratings)

Leonardo DRS, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRS#NASDAQ">DRS</a>) announced today that it was awarded a contract to provide and integrate the latest Battle Management Systems (BMS) C4I hardware and software into new Royal Thailand Army combat vehicles. The total value of the award is more than $7 million. The contract was awarded by the U.S. Army through the U.S. Government Grant Assistance program.
Under the contract Leonardo DRS will provide its ruggedized C4I Battle Management System (BMS) hardware and is the lead integrator for the technology. The work includes integrating BMS software, cyber protection, network integration, training, and sustainment capability for newly acquired Stryker vehicles in the Royal Thailand Army. Leonardo DRS will be supported by a local Thai defense company, Chaiseri Defense, for the installation, training, and in-country support for this program.

Contracts

Leonardo DRS Awarded ~$7M Contract To Integrate Critical C4I Capabilities Into New Royal Thailand Army Stryker Vehicles

Achilles Therapeutics (ACHL) has released an update. Achilles Therapeutics has halted its TIL-based cNeT therapy development and is closing its CHI...

Achilles Therapeutics Shifts Strategy, Seeks Alternatives

Achilles climbs after decision to find strategic alternatives

Achilles Therapeutics GAAP EPS of -$0.48

Achilles Therapeutics (ACHL) has released an update. Achilles Therapeutics has reported a cash position of $86.1 million as of September 30, 2024, ...

Achilles Therapeutics Explores Strategic Options Amid Financial Update

Achilles Therapeutics Plc ( ($ACHL) ) has released its Q3 earnings. Here is a breakdown of the information Achilles Therapeutics Plc presented to i...

Achilles Therapeutics Reports Q3 2024 Financial Results

Achilles Therapeutics (ACHL) has released an update. Achilles Therapeutics has successfully regained compliance with Nasdaq's minimum bid price req...

Achilles Therapeutics Regains Nasdaq Compliance, Boosting Investor Confidence

Achilles Therapeutics (ACHL) announced that it has transferred the commercial license of data and samples from the TRACERx Non-Small Cell Lung Canc...

Achilles Therapeutics sells technology assets to AstraZeneca for $12M

Achilles Therapeutics sells technology assets to AstraZeneca

Achilles Therapeutics ( ($ACHL) ) just unveiled an update. Achilles Therapeutics has sold its technology assets, including data and samples from th...

Achilles Therapeutics Sells Technology Assets to AstraZeneca for $12 Million

The latest announcement is out from Achilles Therapeutics ( ($ACHL) ). Achilles Therapeutics announced the resignation of three members from its Bo...

Achilles Therapeutics Announces Board Resignations Amid Strategic Realignment

ACHL

AZNCF

Health Care

Press Releases

Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning

Comments

Achilles Therapeutics

空売り

Achilles Therapeutics (NASDAQ:ACHL) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル